KRYS Krystal Biotech Inc

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day.

A webcast of the presentation will be available beginning at 1:30 pm ET on Tuesday, November 12, 2024 and will be posted on the Investors section of the Company’s .

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on and (formerly Twitter).

CONTACT

Investors and Media:                                                                                        

Stéphane Paquette

Krystal Biotech

                                                                                  



EN
06/11/2024

Underlying

KRYSKrystal Biotech Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Krystal Biotech Inc

 PRESS RELEASE
Free
KRYS Krystal Biotech...

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- (“Jeune”), a wholly owned subsidiary of (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Dir...

January 14, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces Early Evidence of Monotherapy Activity in He...

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercia...

December 18, 2024 1 EN
Free Trial
KRYS Krystal Biotech...

Krystal Biotech Inc: 2 directors

Two Directors at Krystal Biotech Inc sold 50,000 shares at between 164.781USD and 164.820USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...

KRYS KRYSTAL BIOTECH INC
12/14/24 December 14, 2024 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory...

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and well tolerated at all dosing regimens evaluated to date Conditional sanctioning of the KB407 Phase 1 CF Study CORAL-1 protocol by CFF TDN Investor call and webcast to b...

December 12, 2024 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of ...

Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Explanation regarding the Company’s Marketing Authorization Application for beremagene geperpavec-svdt (B-VEC...

December 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch